Business
ASX to rise, Pfizer bolsters vaccine bets – The Australian Financial Review
Australian shares are poised to open lower after Wall Street shares sold off late in the session amid concerns surging virus cases will prompt wider lockdowns.
Pfizer and its partner BioNTech plan to submit the data to other regulatory agencies around the world and submit data from the study to a peer-reviewed scientific journal.
Pfizer reiterated that it expects to make as many as 50 million vaccine doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.
“In my view, what stocks have not fully priced is more likely to be the 6+ month outlook that could benefit from expedited vaccine availability as opposed…
-
General23 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off
-
General23 hours agoTruck driver charged with causing death by dangerous driving after highway crash
-
Noosa News21 hours agoGyrocopter pilot injured in crash-landing on K’Gari, north of Brisbane
-
General18 hours agoLiberals offer help to start-ups and set goal for small business growth